© Reuters. Biomarin Pharma Earnings, Revenue Beat in Q1
Investing.com – Biomarin Pharma (NASDAQ:) reported on Wednesday first quarter that beat analysts’ forecasts and revenue that topped expectations.
Biomarin Pharma announced earnings per share of $0.63 on revenue of $519.4M. Analysts polled by Investing.com anticipated EPS of $0.2024 on revenue of $511.08M.
Biomarin Pharma shares are down 45.16% from the beginning of the year, still down 14.75% from its 52 week high of $94.20 set on February 10. They are under-performing the Nasdaq which is down 20.17% from the start of the year.
Biomarin Pharma shares gained 2.10% in after-hours trade following the report.
Biomarin Pharma follows other major Healthcare sector earnings this month
Biomarin Pharma’s report follows an earnings beat by UnitedHealth on April 14, who reported EPS of $5.49 on revenue of $80.15B, compared to forecasts EPS of $5.36 on revenue of $78.73B.
J&J had beat expectations on April 19 with first quarter EPS of $2.67 on revenue of $23.43B, compared to forecast for EPS of $2.59 on revenue of $23.62B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar
Be the first to comment